Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
COCorcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated (CORT)

NASDAQ Capital Market · Currency in USD
$85.86 ▼ -21.64 (-20.13%)
At close: Oct 23, 4:00 PM ET. Market closed.
$86.98 ▲ +1.12 (+1.30%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$107.50
Open
$106.05
Day's Range
$84.13 – $106.09
52 Week Range
$28.66 – $126.38
Volume
3,096,127
Avg. Volume
1,170,911
Market Cap
$9.28B
Beta (5Y Monthly)
0.45
PE Ratio (TTM)
165.12
EPS (TTM)
$0.52
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$125.33

Profile: Corcept Therapeutics Incorporated

Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full-time employees
730
CEO
Joseph K. Belanoff

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $0.79 · Revenue est. $323.90M
DateEst.Actual
Jul 29, 2026$0.02$0.36Beat
Apr 30, 2026-$0.11-$0.30Miss
Feb 24, 2026$0.33$0.20Miss
Nov 4, 2025$0.18$0.16Miss
Jul 31, 2025$0.23$0.29Beat
May 5, 2025$0.17$0.17Beat

Analyst view

Consensus price target
$125.33 ▲ +46.0%
Range $50.00 – $165.00
Rating: Buy
Buy 54% · Hold 35% · Sell 12%

Similar stocks

Get free alerts on CORT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.